At a glance
- Originator Eisai Co Ltd
- Class Piperazines
- Mechanism of Action Calcium channel antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Stroke
Most Recent Events
- 15 Dec 2003 No development reported - Preclinical for Stroke in Japan (unspecified route)
- 18 Sep 2001 Preclinical development for Stroke in Japan (Unknown route)